In the past few years, angiotensin II-receptor blockers have become available and are being heavily marketed and increasingly used. In various ways they differ from angiotensin-converting enzyme inhibitors (ACEIs). Until
Introduction
Over the past 2 years, the greatest relative growth in sales of hypertensive drugs in the US has been among the angiotensin II-receptor blockers (ARBs) (Figure 1 ). At the same time, sales of angiotensinconverting enzyme inhibitors (ACEIs) have continued to increase, although they remain below both diuretics and calcium antagonists in total usage. Similar figures have been noted in most other countries with the exception of Japan where ARBs have not yet been approved, most likely because none have been developed by Japanese pharmaceutical companies.
The rapid growth of ARBs have occurred in large part because of the intensive and effective marketing of the most recently introduced class of antihyper- tensive drug. The newness of this class has contributed further to their use by those practitioners who are attracted to the latest fashions in medicine, while at the same time it has held back their use by those more conservative practitioners who change their prescribing habits only slowly, if at all. Overall, the marketing of this new class has overcome a good deal of the hesitation since many more prescriptions have been written than would be expected if they were used only in the situation recommended by both the US Joint National Committee (JNC-6) 1 and the World Health Organization/ International Society of Hypertension (WHO/ISH), 2 namely in those patients who cannot tolerate an ACEI because of cough.
Part of the rapid growth in the ARB family reflects the availability of a drug that has few adverse effects beyond that noted with placebo. 3 Every practitioner has patients who have experienced side effects from virtually every class of antihypertensive drugs, so there is a natural inclination to use a drug that is not only new and therefore untried but also that promises better acceptability by those who have 'been through the lot'.
Differences between ARBs and ACEIs
The recommendations of both the 1997 JNC-6 and the 1999 WHO/ISH guidelines that ARBs are specifically indicated only in patients who should be given an ACEI but who cannot tolerate that choice because of a cough, may give rise to the perception that the two classes are essentially the same-except for the absence of cough with the ARBs. Increasingly convincing evidence shows that they are different in a number of ways, differences which may end up favouring one over the other or which may recommend they be used together for effects additive to what one alone can provide.
Before further considerations of the clinical use of these drugs, a brief review of the fundamentals of their mechanisms of action will be provided. ACEIs act to inhibit the activity of the ACE enzyme, which converts the impotent angiotensin I to the potent angiotensin II, while at the same time it breaks down bradykinin to inactive fragments ( Figure 2 ). 4 The traditional pathway for angiotensin synthesis, from angiotensinogen to AI to AII, can be circumvented by non-ACE alternative pathways including that involving the enzyme chymase, which has been found in high concentrations in heart muscle. Thus AII may be found in blood and tissues even with effective ACE inhibition.
The most widely recognised functions of angiotensin II are mediated through its binding to the AT 1 receptor on cell membranes. The currently available ARBs, shown as AT1RA in Figure 2 , block the binding of AII upon this receptor. As a consequence of this blockade, circulating levels of AII, with no place to be bound, increase. 5 These increased levels of circulating AII are then free to bind onto other AII receptors, of which the AT 2 receptor is the next best characterised. Although most of the activities mediated by the AT 2 receptor appear to be beneficial so that their stimulation could be useful, there may be other long-term adverse effects mediated through this or other AT receptors which have not yet been recognised (Table 1) . Research into the effects of stimulation of the AT 2 and other angiotensin receptors is ongoing.
Therefore ARBs may be pharmacologically superior to ACEIs by blocking the adverse effects of whatever AII that is synthesized through non-ACE pathways. On the other hand, ARBs may be pharmacologically inferior to ACEIs both because they do not lead to increased levels of bradykinin and because they could lead to detrimental actions mediated through other AII receptors.
The potential benefits of increased bradykinin
The increased levels of bradykinin that are provided when ACEIs inhibit its breakdown are almost certainly responsible for the most common side effect Figure 2 The renin-angiotensin system with the site of blockade of the AT 1 -receptor (AT1RA). of ACEI therapy: a dry, non-productive, hacking cough seen in up to 15% of patients overall. As bothersome as this cough may be, preventing the continued intake of an ACEI by perhaps 5% of patients, the increased levels of bradykinin may also be beneficial in enhancing the overall effectiveness and benefits of ACEI therapy.
Experimental evidence suggests a protective effect of bradykinin 6 and a lesser effectiveness of ARBs than ACEIs in lowering blood pressure and reversing left ventricular hypertrophy. 7 Much more impressive are the data published by Gainer et al 8 in humans (Figure 3) . In their study, 20 normotensive subjects and seven hypertensive patients were studied while on a very low sodium diet that raised the level of their renin-angiotensin activity. They received, randomly, four drugs: a placebo, an ACEI (captopril, 25 mg), the ACEI with a specific bradykinin-receptor antagonist (icatibant acetate) and an Figure 3 The acute changes in mean arterial pressure in seven hypertensive subjects given placebo, the ARB losartan, the ACE inhibitor captopril with the bradykinin inhibitor icatibant, and the ACE inhibitor alone. (Reproduced with permission from Gainer et al, 1998 8 ).
Angiotensin II-receptor blockers NM Kaplan S89 ARB (losartan, 75 mg). As seen in Figure 3 , captopril alone lowered the blood pressure the most whereas captopril plus bradykinin-receptor antagonist was less effective and equal to the effect of the ARB alone. These data are in keeping with an extra effect of the ACEI that is provided by the rise in bradykinin that accompanies its action. Without the extra boost from bradykinin, the ACEI is no more effective than the ARB.
These data are short-term and in subjects with an activated renin-angiotensin system. They do, nonetheless, serve as support for an additional benefit from the rise in bradykinin that accompanies the action of an ACEI. Long-term randomised controlled trials comparing one or another ACEI versus one or another ARB in patients with hypertension, renal damage or heart failure are in progress. When they are published, we will know whether one or another is better or whether they should be used together. Until such data becomes available, the current recommendation-use an ARB only if cough precludes use of an ACEI-seems appropriate.
The long experience with ACEIs
This recommendation is made not on the expectation that ACEIs will turn out to be better than ARBs but rather on the certainty that ACEIs provide numerous benefits based upon the immense 20-year experience with them, benefits which have not yet been clearly documented with ARBs which have been available for less than 5 years.
These benefits of ACEIs, which have not yet been shown to accrue to ARBs, include those shown in Table 2 . Whether or not these multiple beneficial effects of ACEIs will be seen with ARBs is simply not yet known. One comparative trial in elderly patients with heart failure found, quite by surprise, a lower mortality rate in those treated with the ARB losartan than those treated with the ACEI captopril. 17 A larger trial, ELITE II, found no difference.
18
One cross-over trial comparing an ACEI (lisinopril) against an ARB (losartan) in 25 non-diabetic hypertensives found an improvement in insulin sensitivity with the ACEI but not with the ARB. On the other hand, an improvement in insulin sensitivity was found in a study of 5 hypertensive men given losartan for 6 weeks. 19 Obviously more data are needed. Reduction of morbidity and mortality in CHF (Swedberg et al, 1999) 12 Improvement of endothelial dysfunction (Koh et al, 1999) 13 Slow progression of diabetic nephropathy (Lewis et al, 1993) 14 Improvement in peripheral neuropathy in normotensive diabetics (Malik et al, 1998) 15 Increased insulin sensitivity (Fogari et al, 1998) 16 
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Side effects with ARBs
Lastly, ARBs are not entirely benign and free of side effects despite the data from initial observations. With larger experience, angioneurotic oedema was attributed to the ARB losartan in 13 cases through the Netherlands Pharmacovigilance Foundation. 20 One case of dysgeusia has also been attributed to losartan. 21 Only time will tell whether more side effects will surface with larger exposure to these agents.
Conclusion
As for now, the recommendation of both the US JNC-6 and the WHOISH seem appropriate: use ARBs only in those who need an ACEI but who develop a cough. In the near future, much more evidence will be forthcoming to either expand or restrict the use of this interesting new class of antihypertensive drugs.
